For the year ending 2025-12-31, CYCN has $9,985K in assets. $3,240K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 3,240 | 3,232 | ||
| Accounts receivable | 1,000 | 556 | ||
| Prepaid expenses | 384 | 421 | ||
| Other current assets | 11 | 16 | ||
| Total current assets | 4,635 | 4,225 | ||
| Other investment | 5,350 | 5,350 | ||
| Total assets | 9,985 | 9,575 | ||
| Accounts payable | 508 | 390 | ||
| Accrued research and development costs | 198 | 52 | ||
| Accrued expenses and other current liabilities | 194 | 283 | ||
| Total current liabilities | 900 | 725 | ||
| Preferred stock, no par value, 100,000,000 shares authorized and 351,037 shares of series a convertible preferred stock issued and outstanding at december 31, 2025 and 2024 | 0 | 0 | ||
| Common stock, no par value, 400,000,000 shares authorized at december 31, 2025 and 2024 3,925,314 and 2,710,096 shares issued at december 31, 2025 and 2024, respectively 3,821,236 and 2,545,922 shares outstanding at december 31, 2025 and 2024, respectively | 0 | 0 | ||
| Paid-in capital | 280,105 | 276,342 | ||
| Accumulated deficit | -271,020 | -267,492 | ||
| Accumulated other comprehensive loss | - | 0 | ||
| Total stockholders' equity | 9,085 | 8,850 | ||
| Total liabilities and stockholders' equity | 9,985 | 9,575 | ||
Cyclerion Therapeutics, Inc. (CYCN)
Cyclerion Therapeutics, Inc. (CYCN)